← Back to Clinical Trials
Recruiting NCT06443138

NCT06443138 Preparation for Medical and Surgical Procedures in Oncogeriatry.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06443138
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Nice
Condition Geriatric Oncology
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2026-09-11
Primary Completion 2028-05-11

Eligibility & Interventions

Sex All sexes
Min Age 70 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Personalized pre-habilitation program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2026-09-11 with a primary completion date of 2028-05-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Surgical management is one of the most frequently used interventions in the treatment of many cancers, but it can be associated with a high risk of postoperative complications. The maintenance and optimization of functional abilities before, during and after treatment are major for elderly cancer patients, as it is now well established that there is a link between the level of functional capacity and the occurrence of these complications. The scientific literature shows that the benefits of pre- and post-operative training programs, but these benefits only apply to a fraction of the patients adhering to the programs. The modalities of intervention (training load, follow-up, etc.) as well as patient involvement in these programs are major issues that need to be addressed to optimize their benefits. Individualizing pre-habilitation, on the basis of the management of the training load, and therefore objective fatigue, would enable better patient adherence to the program, and optimize its benefits. In this context, the PRIMECHO project aims to individualize pre-habilitation in order to improve functional of patients in the pre-habilitation or accelerated recovery after surgery phase. The aim is for the patient to be in optimum physical condition at the time of the intervention or treatment.

Eligibility Criteria

Inclusion Criteria: * Patient aged 70 or over * Cancer patient with planned surgery, * Mini Mental State Examination score greater than or equal to 24 (performed in advance by the geriatrician), * Patient affiliated to or benefiting from a social security insurance * Signed free and informed consent. Exclusion Criteria: * Inability to walk or perform unsupervised exercises. * Vulnerable people

Contact & Investigator

Central Contact

Rabia Boulahssass, MD

✉ boulahssass.r@chu-nice.fr

📞 04 92 03 41 94

Principal Investigator

Rabia Boulahssass, MD

PRINCIPAL INVESTIGATOR

Centre Hospitalier Universitaire de Nice

Frequently Asked Questions

Who can join the NCT06443138 clinical trial?

This trial is open to participants of all sexes, aged 70 Years or older, studying Geriatric Oncology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06443138 currently recruiting?

Yes, NCT06443138 is actively recruiting participants. Contact the research team at boulahssass.r@chu-nice.fr for enrollment information.

Where is the NCT06443138 trial being conducted?

This trial is being conducted at Nice, France.

Who is sponsoring the NCT06443138 clinical trial?

NCT06443138 is sponsored by Centre Hospitalier Universitaire de Nice. The principal investigator is Rabia Boulahssass, MD at Centre Hospitalier Universitaire de Nice. The trial plans to enroll 20 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology